CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 7 enrolled
Drug / intervention
Dacomitinibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02382796
NCT02382796Phase 2Completed
CompareCT.gov

TREATMENT ACCESS PROTOCOL FOR PATIENTS PREVIOUSLY TREATED WITH DACOMITINIB ON A CLINICAL TRIAL IN JAPAN

Pfizer·interventional·Posted Mar 9, 2015·Updated Jul 2, 2020

In Brief

A Phase 2 clinical trial evaluating Dacomitinib for NSCLC. Completed, enrolled 7 participants across 6 sites.

Detailed Summary

The purpose of this study to permit continued access to dacomitinib for patients who participated in other dacomitinib monotherapy treatment protocols in Japan and have the potential to derive clinical benefit without unacceptable toxicity from continued dacomitinib treatment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNSCLC
CountriesJapan
Collaborators--

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedMar 9, 2015
Enrollment StartJul 10, 2015
Primary CompletionMay 30, 2019
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 11.3 years ago

Interventions

Dacomitinibdrug

Starting at the current dose level in the prior study. Dose reductions and re-escalations are allowed based on tolerability. Patients may continue to be treated with dacomitinib on this protocol as long as there is evidence of clinical benefit in the judgment of the investigator.